Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its ...
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...
The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.
Meanwhile, the first major obesity-related phase 3 trial for orforglipron is set to complete in July. If the data from the ...
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback